Publications by authors named "N Iwahashi"
Balloon pulmonary angioplasty (BPA) is an innovative treatment for chronic thromboembolic pulmonary hypertension (CTEPH). We retrospectively examined the clinical outcomes and complications of BPA at Yokohama City University Hospital (YCUH) between 2012 and 2018. In 2012, we began to conduct BPA sessions in 46 patients with inoperable CTEPH; 34 completed the BPA scheme and the follow-up plan.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the safety and long-term outcomes of primary percutaneous coronary intervention (pPCI) for STEMI performed by less experienced operators under the guidance of experienced operators.
- A total of 775 STEMI patients were divided into two groups based on operator experience, with outcomes suggesting that less experienced operators, when supported by seasoned professionals, had similar rates of cardiovascular events compared to experienced operators.
- The results showed no significant increase in risk for in-hospital mortality or 5-year cardiovascular events for patients treated by less experienced operators, indicating that proper support can ensure safety in pPCI procedures.
Background: The importance of prehospital (PH) electrocardiograms (ECG) recorded by emergency medical services (EMS) for diagnosing coronary artery spasm-induced acute coronary syndrome (CS-ACS) remains unclear.
Methods And Results: We enrolled 340 consecutive patients with ACS who were transported by EMS within 12 h of symptom onset. According to Japanese Circulation Society guidelines, CS-ACS (n=48) was diagnosed with or without a pharmacological provocation test (n=34 and n=14, respectively).
Article Synopsis
- Previous studies showed inconsistent links between PCSK9 levels and cardiovascular event risk due to improper measurement methods.
- This study is a sub-analysis of the REAL-CAD trial, which compared the effects of high and low-dose statin therapy on cardiovascular outcomes in stable coronary artery disease patients.
- The results indicated that neither mature nor furin-cleaved PCSK9 levels effectively predicted major adverse cardiovascular events, suggesting they are not useful markers in statin-treated patients.